Information for the public
Idelalisib (Zydelig), given with a drug called rituximab, is recommended as a possible treatment for adults with:
untreated chronic lymphocytic leukaemia, only if they have certain genetic chatacteristics
chronic lymphocytic leukaemia, only if it has been treated but has come back within 2 years.
Idelalisib should be available on the NHS within 3 months of the guidance being issued.
If you are not eligible for treatment as described above, you should be able to continue taking idelalisib until you and your doctor decide it is the right time to stop.